(107, 108), analyzing tumor re-biopsy acquired resistance pathways is critical for next-generation RET TKIs, especially when there is an acquired resistance mutation spectrum difference between selpercatinib and pralsetinib. The gene discussed is RET; the disease is neoplasm.